Compare Hasbro, Inc. (HAS) vs Medpace Holdings Inc (MEDP) Price & Performance

Hasbro (HAS) surged 8.87% to $88.78, driven by strong Q2 2026 earnings that beat estimates with $1.14 billion revenue (up 16% YoY) and raised full-year guidance. Technicals show bullish momentum near resistance at $85, while fundamentals reveal mixed signals: positive cash flow trends and robust Wizards segment growth contrast with negative net income margins and high debt levels. Analyst sentiment is optimistic, with a consensus price target of $104.75 and no sell ratings among 33 covered analysts.

The outlook is cautiously positive, with Magic: The Gathering fueling growth, but risks include elevated valuation multiples (P/E 25.6, EV/EBITDA 41.99) and persistent profitability challenges. Investors may see upside if execution continues, though leverage and margin pressures warrant monitoring.

MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.

The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.